Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902574 | 0.75 | NPC1 (0.41) | LMNAKDM4EALDH1A1KMT2ANPC1 | |
| SCHEMBL2390767 | 0.74 | NOTUM (0.39) | NOTUM | |
| SCHEMBL41608 | 0.72 | NOTUM (0.59) | LMNAKDM4EALDH1A1KMT2ANOTUM | |
| SCHEMBL896573 | 0.72 | — | — | |
| SCHEMBL29635627 | 0.72 | KDM4E (0.50) | LMNAKDM4EALDH1A1KMT2ANOTUM | |
| SCHEMBL173802 | 0.72 | KDM4E (0.50) | LMNAKDM4EALDH1A1KMT2ANOTUM | |
| SCHEMBL1235012 | 0.72 | POLB (0.31) | — | |
| SCHEMBL4540542 | 0.72 | KDM4E (0.46) | LMNAKDM4EALDH1A1KMT2ANOTUM | |
| SCHEMBL15363768 | 0.71 | LMNA (0.49) | LMNAKDM4EALDH1A1KMT2ANOTUM | |
| Hydrochloric Acid SCHEMBL28859111 | 0.71 | LMNA (0.49) | LMNAKDM4EALDH1A1KMT2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3558980-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2021-01-27 | — | — | EP | claimed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | claimed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | claimed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | claimed |
| WO-2018115275-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-06-28 | — | — | WO | claimed |
| CN-104817534-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | ALTANA PHARMA AG | 2015-08-05 | — | — | CN | claimed |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | claimed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | claimed |
| US-20080167301-A1 | Respiratory system disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | claimed |
| CN-101128432-A | Tetrahydroisoquinoline compounds for treatment of cns disorders | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | claimed |
| EP-1856092-A1 | 6-HETEROARYL-1,2,3,4,4A,10B-HEXAHYDRO-PHENANTHRIDINES AS PDE-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Nycomed GmbH (DE) | 2007-11-21 | — | — | EP | claimed |
| EP-1831173-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-12 | — | — | EP | claimed |
| CN-1922170-A | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 | ALTANA PHARMA AG (DE) | 2007-02-28 | — | — | CN | claimed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2006092417-A1 | 6 -HETEROARYL-1, 2, 3,4,4A, 1OB-HEXAHYDRO-PHENANTHRIDINES AS PDE-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | NYCOMED GMBH (DE) | 2006-09-08 | — | — | WO | claimed |
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | US | claimed |
| WO-2006066197-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS FOR TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-22 | — | — | WO | claimed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194837-A1 | Tetrahydroisoquinoline compounds | HRH3, HRH4, HRH1 | LMNA 4705/4885KDM4E 2643/4885ALDH1A1 2450/4885 |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | LMNA 2945/4885KDM4E 933/4885ALDH1A1 1658/4885 |
| US-20080167301-A1 | Respiratory system disorders | PDE4A, PDE4B, PDE12 | LMNA 3908/4885KDM4E 1552/4885ALDH1A1 300/4885 |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | NISCH, TK2, FDPS | LMNA 2945/4885KDM4E 933/4885ALDH1A1 1658/4885 |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | HTT, HYPK, HDAC6 | LMNA 1244/4885KDM4E 2884/4885ALDH1A1 1248/4885 |
| US-20120083476-A1 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, DBH | LMNA 3037/4885KDM4E 1200/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.